Metpure-AM 2.5 Tablet is a combination medication formulated to assist in the management of elevated blood pressure and heart rate. Additionally, it serves therapeutic purposes for angina, which is chest pain linked to heart issues, as well as for arrhythmias and chronic heart failure. The administration of Metpure-AM 2.5 can be done at any point during the day, either on an empty stomach or following a meal; however, it is advisable to maintain a consistent schedule for taking the tablet daily. It is crucial to adhere to the treatment plan prescribed by your healthcare provider, as discontinuing the medication without professional guidance can lead to a worsening of your condition, since high blood pressure frequently presents with no noticeable symptoms. Engaging in regular physical activity, maintaining a healthy weight, and following a balanced diet will further assist in managing blood pressure levels. You may experience side effects such as headaches, swelling of the ankles, rashes on the skin, a slowed heart rate, feelings of nausea, and depression. Users may also experience dizziness, so it is recommended to avoid driving or tasks requiring full attention until you become familiar with how this medication affects you. This medication may elevate potassium levels in the bloodstream, thus it is important to steer clear of potassium-rich foods or supplements. While undergoing treatment, regular monitoring of blood pressure, kidney function, and electrolyte levels may be necessary. Prior to initiating therapy, it’s essential to inform your physician if you have pre-existing liver or kidney issues. Pregnant or breastfeeding individuals should seek medical advice before using this medication. Additionally, disclose any other medications you are currently taking, particularly those for managing blood pressure or heart-related conditions.
-15%

METPURE AM 2.5 (Amlodipine (2.5mg) + Metoprolol Succinate (25mg))
Original price was: ₹203.10.₹173.32Current price is: ₹173.32.
Add to cart
Buy Now

Reviews
There are no reviews yet.